JP2021521103A - 物質使用障害の処置におけるガボキサドールの使用 - Google Patents

物質使用障害の処置におけるガボキサドールの使用 Download PDF

Info

Publication number
JP2021521103A
JP2021521103A JP2020554433A JP2020554433A JP2021521103A JP 2021521103 A JP2021521103 A JP 2021521103A JP 2020554433 A JP2020554433 A JP 2020554433A JP 2020554433 A JP2020554433 A JP 2020554433A JP 2021521103 A JP2021521103 A JP 2021521103A
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
gaboxadol
certain embodiments
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020554433A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521103A5 (https=
Inventor
マシュー・デューリング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ovid Therapeutics Inc
Original Assignee
Ovid Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ovid Therapeutics Inc filed Critical Ovid Therapeutics Inc
Publication of JP2021521103A publication Critical patent/JP2021521103A/ja
Publication of JP2021521103A5 publication Critical patent/JP2021521103A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Addiction (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020554433A 2018-04-06 2019-04-06 物質使用障害の処置におけるガボキサドールの使用 Pending JP2021521103A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862653641P 2018-04-06 2018-04-06
US62/653,641 2018-04-06
US201862654786P 2018-04-09 2018-04-09
US62/654,786 2018-04-09
PCT/US2019/026218 WO2019195813A1 (en) 2018-04-06 2019-04-06 Use of gaboxadol in the treatment of substance use disorders

Publications (2)

Publication Number Publication Date
JP2021521103A true JP2021521103A (ja) 2021-08-26
JP2021521103A5 JP2021521103A5 (https=) 2022-04-11

Family

ID=68101544

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020554433A Pending JP2021521103A (ja) 2018-04-06 2019-04-06 物質使用障害の処置におけるガボキサドールの使用

Country Status (10)

Country Link
US (2) US20190321341A1 (https=)
EP (1) EP3761979A4 (https=)
JP (1) JP2021521103A (https=)
KR (1) KR20210039324A (https=)
CN (1) CN112601524A (https=)
AU (1) AU2019249277A1 (https=)
CA (1) CA3095682A1 (https=)
IL (1) IL277805A (https=)
MX (1) MX2020010545A (https=)
WO (1) WO2019195813A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2022514194A (ja) 2018-11-21 2022-02-10 セルテゴ セラピューティクス インコーポレイテッド 自殺のリスクを低減し、うつ病を迅速に軽減するためのガボキサドール
MX2022014599A (es) 2020-05-20 2022-12-16 Certego Therapeutics Inc Gaboxadol deuterado en anillo y su uso para el tratamiento de trastornos psiquiatricos.
WO2023168023A1 (en) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-crystals or salts comprising psilocin

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508236A (ja) * 2003-06-25 2007-04-05 ハー・ルンドベック・アクチエゼルスカベット うつ病およびその他の情動障害を治療する方法
CN101168057A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 多巴胺激动剂制剂
CN101168058A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 一种混合物制剂
CN101168056A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 混合物制剂
JP2008538748A (ja) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
JP2011522020A (ja) * 2008-06-03 2011-07-28 レノボ・リミテッド 瘢痕を抑制する薬剤および方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6890951B2 (en) * 1998-08-05 2005-05-10 Brookhaven Science Associates Llc Treatment of addiction and addiction-related behavior
IT1313585B1 (it) * 1999-07-30 2002-09-09 Neuroscienze S C A R L Uso di agonisti dei recettori gabab per la terapia di mantenimentodell'astinenza da nicotina in soggetti nicotino-dipendenti.
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
US20020165217A1 (en) * 2001-05-01 2002-11-07 Pfizer Inc. Combination treatment for anxiety and depression
US20050234093A1 (en) * 2003-06-25 2005-10-20 H. Lundbeck A/S Treatment of depression and other affective disorders
CL2004001603A1 (es) * 2003-06-25 2005-05-27 Lundbeck & Co As H Uso de gabaxadol para preparar un medicamento util para el tratamiento del dolor neuropatico.
WO2011069860A1 (en) * 2009-12-08 2011-06-16 Chr. Hansen A/S Novel use for the treatment of metabolic endotoxemia
WO2012027326A2 (en) * 2010-08-24 2012-03-01 The Regents Of The University Of California Methods of treating alcohol intoxication, alcohol use disorders and alcohol abuse which comprise the administration of dihydromyricetin

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007508236A (ja) * 2003-06-25 2007-04-05 ハー・ルンドベック・アクチエゼルスカベット うつ病およびその他の情動障害を治療する方法
JP2008538748A (ja) * 2005-04-07 2008-11-06 ハイシアム， インコーポレイテッド 不安、物質乱用及び依存の予防のための改良型方法及び組成物
CN101168057A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 多巴胺激动剂制剂
CN101168058A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 一种混合物制剂
CN101168056A (zh) * 2006-10-26 2008-04-30 昆明艾迪康生物科技有限公司 混合物制剂
JP2011522020A (ja) * 2008-06-03 2011-07-28 レノボ・リミテッド 瘢痕を抑制する薬剤および方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
EXSPERIMENTAL'NAYA I KLINICHESKAYA FARMAKOLOGIYA, vol. 63(1), JPN6023001281, 2000, pages 19 - 23, ISSN: 0005243213 *
NEUROPHARMACOLOGY, vol. 63, JPN6023001280, 2012, pages 555 - 564, ISSN: 0005243214 *

Also Published As

Publication number Publication date
US20220241253A1 (en) 2022-08-04
AU2019249277A1 (en) 2020-10-22
MX2020010545A (es) 2021-01-08
CA3095682A1 (en) 2019-10-10
CN112601524A (zh) 2021-04-02
KR20210039324A (ko) 2021-04-09
EP3761979A1 (en) 2021-01-13
US20190321341A1 (en) 2019-10-24
EP3761979A4 (en) 2021-06-30
WO2019195813A1 (en) 2019-10-10
IL277805A (en) 2020-11-30

Similar Documents

Publication Publication Date Title
JP7730443B2 (ja) オピオイド過剰摂取を処置するための組成物および方法
CN101626766B (zh) 药用组合物的改进和与药用组合物相关的改进
KR101698182B1 (ko) 날록손을 포함하는 비강내 제약 투여 형태
JP4898073B2 (ja) 鼻内投与用フェンタニル組成物
HK1231370A1 (zh) 鼻用药物产品及其使用方法
US20220241253A1 (en) Use of gaboxadol in the treatment of substance use disorders
EP3876937A1 (en) Methods, parenteral pharmaceutical formulations, and devices for the prevention of opioid overdose
KR20140014350A (ko) 정맥 내 투여용 이부프로펜의 투여
JP7797440B2 (ja) 治療方法及びその剤形
AU2022323269A1 (en) Compositions and methods for the treatment of opioid overdose
HK40050846A (en) Use of gaboxadol in the treatment of substance use disorders

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220401

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220401

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230117

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230127

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230613

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240123